← All Kura Oncology, INC filings

Kura Oncology, INC 8-K filings

NASDAQ
KURA
Kura Oncology, INC
8-K: Kura Oncology Reports Positive Clinical Trial Data and Strong Financial Position
Kura Oncology announced positive preliminary data from its ziftomenib combination trials, along with a strong cash position extending into 2027.
NASDAQ
KURA
Kura Oncology, INC
8-K: Kura Oncology Announces Positive Preliminary Data for Ziftomenib Combination Therapy and Secures $146 Million in Private Placement
Kura Oncology reports promising early clinical results for ziftomenib in combination with standard therapies for AML, alongside a successful $146 million private placement, extending their cash runway into 2027.
NASDAQ
KURA
Kura Oncology, INC
8-K: Kura Oncology Secures $150 Million in Oversubscribed Private Placement
Kura Oncology has successfully raised $150 million through an oversubscribed private placement, extending its operational runway into 2027.